Access to investigational drug for continued treatment
Part of Cancer clinical trials.
This program provides access to an investigational drug for people who have already been part of the main clinical trial and have no other treatment options. It aims to give continued treatment when regular access is not possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be enrolled in the main study of this drug to qualify.
- This program is for people who have completed or are no longer able to take part in the main clinical trial.
- Your doctor must confirm that no other treatment options are available for your condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
This trial provides access to an investigational drug called ABBV-706 for people who have no other standard treatment options. It aims to offer treatment when no other clinical trials are available.
This program provides access to an investigational drug for people with advanced solid tumors when no other treatment options are available.
This trial tests an investigational drug given through an IV to see if it can help people with advanced solid tumors. It aims to learn about side effects, how the drug works in the body, and whether it can slow or shrink the cancer.
This trial tests a new drug called ABL103 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
This program provides access to two investigational drugs, balstilimab and zalifrelimab, for people who have already completed a related clinical trial. It aims to offer continued treatment options for those who may benefit.
Hear when a new Advanced Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.